Eris Lifesciences (ERIS) Q3 25/26 earnings summary

Executive summary

• Q3 and nine-month results showed strong growth in branded formulations, international business, and consolidated operations, with record consolidated revenue of INR 807 crore in Q3, up 11% year-on-year, and adjusted PAT up 38.5% year-on-year.

• International business achieved its highest-ever quarterly revenue, up 45% year-on-year, and EBITDA up 46%.

• Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved with unmodified auditor opinions.

• The company operates primarily in the pharmaceuticals segment, with recent expansions and acquisitions impacting group structure.

Financial highlights

• Branded Formulations Q3 revenue: INR 696 crore; nine months: INR 2,106 crore; EBITDA for Q3: INR 254 crore; nine months: INR 781 crore.

• International business Q3 revenue: INR 111 crore (45% growth); nine months: INR 259 crore (11% growth); Q3 EBITDA margin: 30%.

• Consolidated Q3 revenue: INR 807 crore (11% growth); nine months: INR 2,373 crore; Q3 operating profit: INR 282 crore (13% growth); Q3 EPS: INR 9.

• Consolidated net profit for the quarter was INR 108.83 crore, and for nine months, INR 368.40 crore.

• Exceptional item of INR 17 crore in Q3 due to new labour code, increasing employee-related liabilities.

Outlook and guidance

• Branded Formulations expected to close the year with 13%-14% growth and EBITDA margin above 39% (excluding discontinued brands).

• Full-year consolidated revenue guidance: INR 3,200 crore (12% growth, excluding trade generics); EBITDA guidance: INR 1,150 crore (15% growth).

• FY 2027 projected as a breakout year for international business, with revenue of INR 550-600 crore and EBITDA of INR 180-200 crore.

• Net debt to EBITDA ratio targeted at 1.5x by year-end.

• The company completed the acquisition of the remaining 30% stake in Swiss Parenterals Limited, making it a wholly owned subsidiary as of January 16, 2026.